Evidence grows for use of amyloid PET in China

Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia.In patients treated at a memory clinic at Huashan Hospital in Shanghai, amyloid PET scans detected brain pathology associated with the disease and led to changes in treatment plans in 36.5% of patients, noted lead author Ke-Liang Chen, MD, a neurologist at Fudan University.“In this large, real-world study, we found that [beta amyloid]-PET led to the changes in etiological diagnosis, diagnostic confidence, and treatment plan, providing new evidence for the use of [amyloid beta]-PET in Chinese population,” the group wrote.The clinical utility of amyloid PET scans has been systematically studied in many other countries. These scans detect beta-amyloid plaque deposits, one of the hallmarks of Alzheimer’s disease, using radiotracers that bind to beta-amyloid cells.Yet only a few studies with small sample sizes have been performed in Chinese participants, the researchers wrote. Moreover, due to this lack of evidence, amyloid PET scans have yet to be reimbursed by the Chinese medical insurance system, they added.To address this evidence gap, between 2019 and 2023, the researchers recruited 1,073 patients to participate in a trial. All patients underwent PET scans using F-18 florbetapir (Amyvid, Avid Radiopharmaceuticals), an amylo...
Source: AuntMinnie.com Headlines - Category: Radiology Authors: Source Type: news